Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12363720 | 0.95 | RAB9A (0.53) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL1938838 | 0.92 | CYP3A4 (0.64) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL1939659 | 0.86 | CYP3A4 (0.55) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL1937729 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL1939315 | 0.84 | KDM4E (0.58) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL1939311 | 0.83 | CYP3A4 (0.59) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL1939620 | 0.80 | CYP3A4 (0.62) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL1939052 | 0.79 | CYP3A4 (0.51) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E | |
| SCHEMBL8125365 | 0.77 | ALDH1A1 (0.60) | SMN1; SMN2RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL1938820 | 0.77 | CYP3A4 (0.70) | SMN1; SMN2RAB9ACYP3A4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | claimed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | claimed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | disclosed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | SMN1; SMN2 4623/4885RAB9A 2116/4885CYP3A4 1871/4885 |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | SMN1; SMN2 4623/4885RAB9A 2116/4885CYP3A4 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.